Bayer has been granted a patent for dihydrooxydiazinone compounds, which can be used in the treatment or prevention of hyperproliferative diseases. The patent also covers methods of preparing the compounds, intermediate compounds, pharmaceutical compositions, and combinations with other active ingredients. GlobalData’s report on Bayer gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bayer AG - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bayer, Peptide pharmacophores was a key innovation area identified from patents. Bayer's grant share as of September 2023 was 57%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11773070B2) discloses a compound with a specific structure that has potential applications in the field of pharmaceuticals. The compound is the subject of several claims in the patent.

Claim 1 describes the compound itself, highlighting its unique structure. This compound is the basis for the subsequent claims in the patent.

Claim 2 introduces a pharmaceutical composition that includes the compound from claim 1 along with one or more pharmaceutically acceptable excipients. This composition could potentially be used in the development of new drugs.

Claim 3 expands on claim 2 by proposing a pharmaceutical combination that includes the compound from claim 1 and one or more additional anti-cancer agents. This combination could be used in the treatment of diseases sensitive to phosphodiesterase 3A (PDE3A) or phosphodiesterase 3B (PDE3B) modulation.

Claim 4 outlines a method for treating a disease sensitive to PDE3A or PDE3B modulation by administering the compound from claim 1 to a subject. This method could have implications in the treatment of various diseases.

Claim 5 specifies that the disease being treated in claim 4 is a hyperproliferative disease. Hyperproliferative diseases are characterized by abnormal cell growth and division.

Claim 6 further specifies that the hyperproliferative disease being treated in claim 5 is a cancer disease. This claim highlights the potential application of the compound in cancer treatment.

Claims 7, 8, and 9 provide specific examples of cancer diseases that could be targeted using the method described in claim 6. These include brain cancer, breast cancer, cervical cancer, AML, lung cancer, skin cancer, esophageal carcinoma, ovarian cancer, pancreas cancer, prostate cancer, glioma, glioblastoma, and melanoma.

Overall, this granted patent presents a compound with a specific structure that could be used in the development of pharmaceutical compositions and combinations for the treatment of hyperproliferative diseases, particularly cancer. The patent provides a method for administering the compound to subjects with diseases sensitive to PDE3A or PDE3B modulation, potentially opening up new avenues for treatment in various cancer diseases.

To know more about GlobalData’s detailed insights on Bayer, buy the report here.

This content was updated on 25 January 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies